Last Updated : May 3, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Vonvendi | von Willebrand Factor [recombinant] | von Willebrand disease, adults, treatment and perioperative management | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imbruvica | Ibrutinib | Waldenstrom's Macroglobulinemia | Do not reimburse | Complete | ||
| Imbruvica | ibrutinib | Waldenström’s Macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Wegovy | semaglutide | Weight management | Do not reimburse | Complete | ||
| Waymade-Trientine | trientine hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| MAR-Trientine | Trientine Hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 3, 2024